Actively Recruiting
Upadacitinib for Prurigo Nodularis
Led by Psoriasis Treatment Center of Central New Jersey · Updated on 2025-01-15
25
Participants Needed
1
Research Sites
90 weeks
Total Duration
On this page
Sponsors
P
Psoriasis Treatment Center of Central New Jersey
Lead Sponsor
A
AbbVie
Collaborating Sponsor
AI-Summary
What this Trial Is About
A single center, open-label study of 25 subjects to assess 24 weeks upadacitinib in patients with moderate-to-severe prurigo nodularis.
CONDITIONS
Official Title
Upadacitinib for Prurigo Nodularis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female adults aged 18 to 64 years at screening
- Diagnosis of prurigo nodularis for 3 months or longer
- Moderate-to-severe prurigo nodularis with at least 10 lesions on legs, arms, or trunk
- Failure of a 2-week course of medium to super potent topical corticosteroids or corticosteroids not medically advisable
- Females of childbearing potential must have negative pregnancy tests and use effective birth control during and 30 days after the study
- Candidate for systemic therapy as determined by the investigator
- Able and willing to provide written informed consent
- In general good health based on medical history and physical exam
You will not qualify if you...
- Presence of skin conditions other than prurigo nodularis or atopic dermatitis interfering with assessments
- Diagnosis of active atopic dermatitis at screening and baseline
- Prurigo nodularis caused by medications or medical conditions such as neuropathy or psychiatric disease
- Severe uncontrolled illnesses that could affect study participation
- Severe kidney conditions such as uremia or dialysis
- Uncontrolled thyroid disease
- Active or incompletely treated tuberculosis or other mycobacterial infections without adequate treatment
- Active or suspected endoparasitic infections unless ruled out before enrollment
- Active infections requiring systemic treatment within 2 weeks before screening
- Known or suspected immunodeficiency
- Active cancer or history of malignancy within 5 years except certain resolved skin or cervical cancers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Eczema Treatment Center of New Jersey
East Windsor, New Jersey, United States, 08520
Actively Recruiting
Research Team
A
Ashley Reed
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here